Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Pancreatic cancer treatment enters new era

Pancreatic cancer treatment enters new era

New Capabilities

First New Treatment in 30 Years Launches; Early Data Points to Metastatic Disease as Next Target

April 30th, 2026: Novocure Q1 2026 Earnings: 83 Patients on Optune Pax After Seven Weeks

Overview

Updated Jun 3

Pancreatic cancer kills roughly 52,000 Americans each year and carries a five-year survival rate of 13 percent. In February 2026, the FDA approved Optune Pax, the first new treatment for locally advanced disease in nearly 30 years, adding alternating electric fields to the treatment options alongside chemotherapy.

The launch moved quickly: within seven weeks, Novocure had certified more than 800 prescribers and started 83 patients on therapy. In March, the company reported Phase 2 results: TTFields achieved a disease control rate of 74.4 percent in metastatic pancreatic cancer, versus 48 percent in a historical control. A Phase 3 trial decision will determine whether TTFields can reach the far larger population of metastatic patients.

Why it matters

TTFields proving effective in metastatic pancreatic cancer would give a real treatment option to most of the 52,000 Americans diagnosed each year.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Play on this story Voices Debate Predict Higher or Lower Timeline Connections

Key Indicators

16.2
Median survival (months)
Patients receiving Optune Pax plus chemotherapy versus 14.2 months with chemotherapy alone
15.2
Pain-free survival (months)
Extended from 9.1 months in chemotherapy-only group, a 6.1-month improvement
13%
Five-year survival rate
Pancreatic cancer remains among the deadliest cancers, though survival has improved from 7% a decade ago
74.4%
PANOVA-4 disease control rate
TTFields with atezolizumab and chemotherapy in metastatic pancreatic cancer, versus 48 percent in the historical control

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 5 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Yoram Palti
Yoram Palti
Novocure Founder and Chief Technology Officer
Active; recipient of 2022 Israel Prize for entrepreneurship
 Ashley Cordova
Ashley Cordova
Chief Executive Officer, Novocure
Former CEO (succeeded, based on recent statement from Frank Leonard)
 Vincent Picozzi
Vincent Picozzi
Medical Oncologist and PANOVA-3 Trial Investigator
Active
 Anna Berkenblit
Anna Berkenblit
Chief Scientific and Medical Officer, Pancreatic Cancer Action Network (PanCAN)
Active
 Frank Leonard
Frank Leonard
Chief Executive Officer, Novocure
Active (noted in recent statement)

Organizations Involved

Novocure
Novocure
Biotechnology Company
Publicly traded; Optune Pax launched in U.S. with 83 patients on therapy after seven weeks; Germany and Japan launches planned for H2 2026; pursuing metastatic indication via PANOVA-4

Developer of tumor treating fields technology, a fourth modality of cancer treatment using alternating electric fields to disrupt cancer cell division.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Granted approval; previously designated Optune Pax as Breakthrough Device in December 2024

Federal agency responsible for approving medical devices and drugs for use in the United States.

Timeline

May 1996 April 2026

13 events Latest: April 30th, 2026 · 4 months ago Showing 8 of 13
Tap a bar to jump to that date

  1. Novocure Q1 2026 Earnings: 83 Patients on Optune Pax After Seven Weeks

    Latest Corporate

    Novocure reported first-quarter revenues of $174 million, up 12 percent year over year. Within seven weeks of launch, Optune Pax had certified 868 prescribers and started 90 patients on therapy; 83 were still active at quarter end.

  2. PANOVA-4 Phase 2: TTFields Shows 74.4% Disease Control Rate in Metastatic Pancreatic Cancer

    Research

    Novocure reported a disease control rate of 74.4 percent in Phase 2 PANOVA-4, nearly double the 48 percent historical benchmark for metastatic pancreatic ductal adenocarcinoma. The trial combined TTFields with atezolizumab and standard gemcitabine plus nab-paclitaxel chemotherapy.

  3. Novocure Q4 2025 Earnings: Germany and Japan Launches Planned for H2 2026

    Corporate

    Two weeks after the FDA approval, Novocure's Q4 2025 earnings call outlined plans to launch Optune Pax in Germany and Japan in the second half of 2026, pending regulatory clearances in each market.

  4. Novocure Releases Detailed PANOVA-3 Data and Physician Statements

    Corporate

    Novocure published detailed Phase 3 PANOVA-3 results showing one-year survival rate of 68.1% with Optune Pax plus chemotherapy vs. 60.2% with chemotherapy alone; included endorsements from trial investigator Vincent Picozzi, M.D., and PanCAN's Anna Berkenblit, M.D.

  5. FDA Approves Optune Pax for Pancreatic Cancer

    Regulatory

    The FDA approved Optune Pax, the first new treatment for locally advanced pancreatic cancer in nearly 30 years. The device delivers tumor treating fields to the abdomen alongside chemotherapy.

  6. PANOVA-3 Results Presented at ASCO

    Research

    Novocure presented final PANOVA-3 trial results at the American Society of Clinical Oncology annual meeting, showing statistically significant overall survival improvement.

  7. Breakthrough Device Designation Granted

    Regulatory

    The FDA granted Breakthrough Device designation to Optune Pax for locally advanced pancreatic cancer, accelerating the review process.

  8. NALIRIFOX Approved for Metastatic Disease

    Regulatory

    The FDA approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin as the NALIRIFOX regimen for first-line treatment of metastatic pancreatic cancer.

  9. Nab-Paclitaxel Combination Approved

    Regulatory

    The FDA approved nab-paclitaxel (Abraxane) for use with gemcitabine in metastatic pancreatic cancer, establishing a new standard combination.

  10. FOLFIRINOX Trial Published

    Research

    The New England Journal of Medicine published results showing the four-drug FOLFIRINOX regimen extended median survival to 11.1 months versus 6.8 months for gemcitabine alone in metastatic pancreatic cancer.

  11. First FDA Approval for Tumor Treating Fields

    Regulatory

    The FDA approved Novocure's Optune device for recurrent glioblastoma, validating the TTFields approach for the first time.

  12. Novocure Founded

    Corporate

    Yoram Palti founded Novocure based on his discovery that alternating electric fields could disrupt cancer cell division.

  13. Gemcitabine Approved for Pancreatic Cancer

    Regulatory

    The FDA approved gemcitabine (Gemzar), establishing the first standard-of-care chemotherapy for advanced pancreatic cancer. It remained the backbone of treatment for decades.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

May 1996

Gemcitabine Approval Changes Pancreatic Cancer Standard of Care (1996)

The FDA approved gemcitabine (Gemzar) for advanced pancreatic cancer based on trials showing improved clinical benefit response over fluorouracil. Approximately one-quarter of patients achieved marked symptom relief. The drug became the backbone of pancreatic cancer treatment.

Then

Gemcitabine established the first evidence-based standard of care for advanced pancreatic cancer, replacing fluorouracil as first-line treatment.

Now

For nearly three decades, gemcitabine remained central to pancreatic cancer treatment. New regimens like FOLFIRINOX and gemcitabine-nab-paclitaxel built upon rather than replaced it. The Optune Pax approval marks the first entirely new modality added since.

Why this matters now

The Optune Pax approval is significant precisely because the treatment landscape has been so static. Adding two months of survival to a gemcitabine-based backbone represents the first non-chemotherapy option for locally advanced patients in 30 years.

April 2011

Optune Approved for Glioblastoma (2011)

The FDA approved Novocure's Optune device for recurrent glioblastoma, making it the first tumor treating fields device to reach market. The approval came after years of medical community skepticism about bioelectronic medicine. Initial adoption was slow.

Then

Oncologists gradually incorporated TTFields into glioblastoma treatment as clinical experience accumulated. Insurance coverage expanded over several years.

Now

The EF-14 trial showed patients using Optune with temozolomide had median survival of 20.8 months versus 16 months for chemotherapy alone—and a 13% five-year survival rate, remarkable for glioblastoma. The success validated TTFields and paved the way for expansion to other cancers.

Why this matters now

The glioblastoma approval demonstrated that TTFields could improve survival in a notoriously difficult cancer. Novocure's subsequent approvals in mesothelioma, non-small cell lung cancer, and now pancreatic cancer follow the same playbook: prove efficacy in Phase 3 trials for cancers with few options.

May 2011

FOLFIRINOX Trial Extends Pancreatic Cancer Survival (2011)

French researchers published results showing the four-drug FOLFIRINOX regimen extended median survival to 11.1 months versus 6.8 months for gemcitabine alone in metastatic pancreatic cancer—a 4.3-month improvement, the largest ever seen in a Phase 3 pancreatic cancer trial at the time.

Then

FOLFIRINOX became the preferred regimen for fit patients with metastatic disease, despite more severe side effects than gemcitabine.

Now

The trial demonstrated that meaningful survival gains were possible in pancreatic cancer and reinvigorated research interest. However, the regimen's toxicity limited its use to patients with good performance status.

Why this matters now

The FOLFIRINOX breakthrough showed that survival improvements of 4+ months were achievable in pancreatic cancer. Optune Pax's 2-month improvement is more modest but represents an entirely different approach—and one that may combine with existing chemotherapy rather than compete with it.

Sources

(16)
+10
U.S. Food and Drug Administration GlobeNewswire CURE Journal of Clinical Oncology Novocure Pancreatic Cancer Action Network National Cancer Institute SEER Program New England Journal of Medicine American Cancer Society OncLive Business Wire SEC EDGAR The Motley Fool Fierce Biotech Novocure The Motley Fool